HK1146705A1 - 作為抗癌劑的自組裝的兩親性聚合物 - Google Patents

作為抗癌劑的自組裝的兩親性聚合物

Info

Publication number
HK1146705A1
HK1146705A1 HK11100809.8A HK11100809A HK1146705A1 HK 1146705 A1 HK1146705 A1 HK 1146705A1 HK 11100809 A HK11100809 A HK 11100809A HK 1146705 A1 HK1146705 A1 HK 1146705A1
Authority
HK
Hong Kong
Prior art keywords
self
anticancer agents
amphiphilic polymers
assembling amphiphilic
assembling
Prior art date
Application number
HK11100809.8A
Other languages
English (en)
Inventor
Anil R Diwan
Ann Louise Onton
Jayant G Tatake
Original Assignee
Allexcel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allexcel Inc filed Critical Allexcel Inc
Publication of HK1146705A1 publication Critical patent/HK1146705A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK11100809.8A 2007-07-19 2011-01-26 作為抗癌劑的自組裝的兩親性聚合物 HK1146705A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/073880 WO2009011702A1 (en) 2007-07-19 2007-07-19 Self-assembling amphiphilic polymers as anticancer agents

Publications (1)

Publication Number Publication Date
HK1146705A1 true HK1146705A1 (zh) 2011-07-08

Family

ID=40259892

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11100809.8A HK1146705A1 (zh) 2007-07-19 2011-01-26 作為抗癌劑的自組裝的兩親性聚合物
HK16112757.0A HK1224232A1 (zh) 2007-07-19 2016-11-07 作爲抗癌劑的自組裝的兩親性聚合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16112757.0A HK1224232A1 (zh) 2007-07-19 2016-11-07 作爲抗癌劑的自組裝的兩親性聚合物

Country Status (15)

Country Link
US (1) US9770442B2 (zh)
EP (1) EP2167103B1 (zh)
JP (1) JP5296787B2 (zh)
KR (1) KR101470679B1 (zh)
CN (1) CN101795695B (zh)
AP (1) AP2941A (zh)
AU (1) AU2007356525B2 (zh)
BR (1) BRPI0721759B1 (zh)
CA (1) CA2691002C (zh)
EA (1) EA200901451A1 (zh)
HK (2) HK1146705A1 (zh)
IL (1) IL202182A (zh)
MX (1) MX341715B (zh)
NZ (1) NZ581210A (zh)
WO (1) WO2009011702A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2009042825A2 (en) * 2007-09-27 2009-04-02 The University Of Akron Process of preparing functionalized polymers via enzymatic catalysis
WO2010138802A2 (en) 2009-05-28 2010-12-02 Cornell University Compositions and their use for removing cholesterol
EP2438908A1 (en) 2010-10-11 2012-04-11 Vectum Pharma, S.L. Anchoring compositions for topical applications
CN103687867B (zh) 2011-05-11 2017-02-08 阿佩利斯制药公司 细胞反应性的、长效的或靶向的坎普他汀类似物及其用途
ES2879430T3 (es) * 2012-11-15 2021-11-22 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
EP3359555B1 (en) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosing regimens
CN110023407B (zh) * 2016-09-20 2021-10-29 康奈尔大学 标记的聚(酯酰胺氨基甲酸酯)、由其形成的纳米粒子和其用途
WO2018175589A1 (en) * 2017-03-22 2018-09-27 The Regents Of The University Of California Modified peptides and uses thereof for treating cancer
MX2019012033A (es) 2017-04-07 2019-12-05 Apellis Pharmaceuticals Inc Regímenes de dosificación y composiciones y métodos relacionados.
US10618023B2 (en) 2017-10-18 2020-04-14 International Business Machines Corporation Formation of a janus microcapsule
CN108354902A (zh) * 2018-05-22 2018-08-03 杭州市肿瘤医院 一种阿帕替尼聚合物胶束及其制备方法
CN111514293A (zh) * 2020-05-03 2020-08-11 大连理工大学 近红外无重原子氟硼吡咯在光动力治疗转移瘤及上转换中的应用
EP4359542A1 (en) * 2021-06-23 2024-05-01 The Johns Hopkins University Methods and materials for treating cancer
WO2022271183A1 (en) * 2021-06-25 2022-12-29 Allexcel Inc. Self-assembling amphphlic polymers as anti-covid-19 agents
KR102671525B1 (ko) * 2022-02-14 2024-05-31 강원대학교산학협력단 극성 양이온성 고분자, 비극성 음이온성 화합물 및 금나노입자를 포함하는 온도 및 산화 응답성 유효성분 전달체 및 이를 포함하는 약학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942243A (en) * 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
EP1063254A1 (de) * 1999-06-25 2000-12-27 Technische Uni München, Klinikum rechts der Isar, Inst. für Experiment. Onkoligie und Therapieforschung Copolymere für den Transport von Nukleinsäuren in die Zelle
US6521736B2 (en) * 2000-09-15 2003-02-18 University Of Massachusetts Amphiphilic polymeric materials
GB0221942D0 (en) * 2002-09-20 2002-10-30 Univ Strathclyde Drug delivery
US7316816B2 (en) * 2004-06-10 2008-01-08 Agency For Science Technology And Research Temperature and pH sensitive copolymers
WO2006113666A2 (en) * 2005-04-19 2006-10-26 Massachusetts Institute Of Technology Amphiphilic polymers and methods of use thereof
EP3449946A3 (en) * 2005-12-19 2020-11-04 PharmaIN Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
PT1979407E (pt) * 2006-01-19 2014-10-16 Allexcel Inc Solubulização e distribuição direcionada de medicamentos com polímeros anfifilicos de automontagem
JP5539733B2 (ja) * 2007-01-22 2014-07-02 オールエクセル，インコーポレイティド 抗ウイルス薬としての自己集合性の両親媒性高分子

Also Published As

Publication number Publication date
EA200901451A1 (ru) 2010-06-30
IL202182A (en) 2015-06-30
EP2167103B1 (en) 2017-03-01
AP2941A (en) 2014-07-31
JP5296787B2 (ja) 2013-09-25
US9770442B2 (en) 2017-09-26
MX341715B (es) 2016-08-23
BRPI0721759A2 (pt) 2014-02-11
BRPI0721759B1 (pt) 2022-04-12
CA2691002A1 (en) 2009-01-22
US20100239659A1 (en) 2010-09-23
CA2691002C (en) 2016-05-10
MX2010000721A (es) 2010-05-24
CN101795695A (zh) 2010-08-04
WO2009011702A1 (en) 2009-01-22
AU2007356525A1 (en) 2009-01-22
AP2010005129A0 (en) 2010-02-28
IL202182A0 (en) 2010-06-16
CN101795695B (zh) 2016-01-06
EP2167103A1 (en) 2010-03-31
HK1224232A1 (zh) 2017-08-18
KR20100038384A (ko) 2010-04-14
EP2167103A4 (en) 2012-11-28
KR101470679B1 (ko) 2014-12-08
AU2007356525B2 (en) 2014-07-17
NZ581210A (en) 2012-04-27
JP2010533710A (ja) 2010-10-28

Similar Documents

Publication Publication Date Title
HK1224232A1 (zh) 作爲抗癌劑的自組裝的兩親性聚合物
AP2523A (en) Self-assembling amphiphilic polymers as antiviral agents
EP2219587A4 (en) STEROL-MODIFIED AMPHIPHILE LIPIDES
IL209602A0 (en) Amphiphilic branched polymers and their use as emulsifiers
EP2226357A4 (en) PROPYLENE POLYMER COMPOSITION
ZA201001576B (en) Catalyst compositions
PT2214504E (pt) Material polimérico anfifílico
HK1151959A1 (en) Retractor
IL211147A0 (en) 1h-benzimidazole-5-carboxamides as anti-inflammatory agents
IL213920A0 (en) 3,3'-spiroindolinone derivatives as anticancer agents
HK1220378A1 (zh) 具有所需生物利用度的藥物組合物
EP2207824A4 (en) THERMOPLASTIC AMPHIPHILIC CO-NETWORKS
IL212839A (en) Organosol preparations with thermosensible phospholipid structure
EP2310363A4 (en) ORAL ANTIBODY FORMULATIONS
EP2367761A4 (en) MOLECULAR SIEVE SSZ-83
EP2240348A4 (en) INFLATABLE SAFETY CUSHION
EP2297218A4 (en) AMPHIPHILIC SEQUENCED COPOLYMER FORMULATIONS
IL212375A0 (en) Naphthamides as anticancer agents
GB0805452D0 (en) Methods for the formation of conjugated polymers
EP1986635A4 (en) ANTI CANCER AGENTS
PT2376060E (pt) Composições de nanopartículas
IL213445A0 (en) Anticancer compounds
HK1147035A1 (zh) 二氫吲哚抗癌劑
IL207859A (en) A combination of cancer treatment preparations
EP2105140A4 (en) CANCER AGENT